参考文献:
1. Lacey D.L, et al., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell (1998),93:165-176.
2. Kong Y.Y.et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.Nature (1999),397:315-323.
3. Hsu H.et al.,Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc NatlAcad Sci (1999),96:3540-3545.
4. Josien R, et al, TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo.JExp Med (2000),191:495-502.
5. Fuller K.et al.,TRANCEis necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. JExp Med (1998),188:997-1001.
6. Nakashima T , et. al., Protein expression and functional difference of membrane bound and soluble receptor activator of NF-kappaB ligand: modulation of theexpression by osteotropic factors and cytokines. Biochem Biophys Res Commun(2000), 275(3):768-75.
7. Kong Y.Y.et al,Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.Nature (1999),402:304-309.
8. Hofbauer L.C.&A.E.Heufelder, Role of receptor activator of nuclear factor-KB ligand and osteoprotegerin in bone cell biology.J Mol Med (2001),79:243-253.
9. Hofbauer L.C.& A.E.Heufelder, The Role of Osteoprotegerin and Receptor Activator of Nuclear Factor KB Ligand in the Pathogenesis and Treatment of Rheumato-id Arthritis.Arthritis & Rheumatism (2001),44:253-259.
10.Hofbauer LC, et al...The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone di-seases.JCin Endocrinol Metab (2000),85: 2355-2363.
11.Teitelbaum S.L., Bone resorption by osteoclasts.Science (2000), 289:1504-1508.
12.Boumans,M.J.H. et al., 2012.Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis.Annals of the rheumatic diseases,71(1),pp.108-13.
13. Dovio, A.et al., 2008.Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.The Journal of rheumatology, 35(11), pp.2206-13.
14.Dovio, A.et al., 2007.Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile.The Journal of clinical endo-crinology and metabolism,92(5),pp.1803-8.
15.Findlay, D. et al., 2008.Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males.Arthritis research & therapy,10(1), p.R2.
16.Gonzélez-Alvaro, l.et al., 2007.Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists.Annals ofthe rheumatic diseases, 66(12), pp.1675-8.
17.Hein, G. et al., 2000. vergleich der Serum- und Synovia-Spiegel von sRANKL und OPG bei rheumatoider Arthritis und nicht erosiven Arthritiden.Poster beim Kon-gress der Deutschen Gesellschaft fur Rheumatologie. Dresden.
18.Hein, G.E. et al.,2008. sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis.Rheumatology international, 28(8), pp.765-9.
19.Hofbauer, L.C. et al., 2004.Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women.Clinicalendocrinology, 60(2).pp.214-9.
20.Kamiya,N. et al, 2011. Significance of serum osteoprotegerin and receptor activator of nuclear factor xB ligand in Japanese prostate cancer patients with bonemetastasis. lnternational journal of clinical oncology,16(4), pp.366-72.
21.Kerschan-Schindl, K. et al., 2008. Serum levels of receptor activator of nuclear fac-
tor kappaB ligand (RANKL) in healthy women and men.Experimental and clinicalendocrinology & diabetes : official journal, German Society of Endocrinology [and]German Diabetes Association, 116(8).pp.491-5.
22.Li, E.K. et al., 2009.High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus.The Journal of rheumatology,36(8), pp.1646-52.
23.Nielen, M. et al.,, 2004.Markers of bone formation and resorption in preclinical rheumatoid arthritis are associated with radiographic progression. Poster beimAmerican College of Rheumatology Meeting. San Diego.
24.Oelzner, P. et al., 2009.Beziehung zwischen loslichen Komponenten des IL-6-Systems und des RANKL-OPG-Systems bei postmenopausalen Frauen mit Rheuma-toider Arthritis.Poster bei Osteologie. Frankfurt.
25.Oelzner, P. et al., 2006.RANKL ,Osteoprotegerin und IlL-6-System bei Rheumatoider Arthritis -EinfluR von Alter ,Erkrankungsdauer , Menopause und entzund-licher Aktivitat.Poster bei Osteologie.Koln.
26.Schederl, J.et al., 2005.P148- Osteoprotegerin, RANK-Ligand und 5b-b TRAP bei Patienten mit Morbus Crohn.Zeitschrift fur Gastroenterologie, 43, p.812.
27.Secchiero, P. et al., 2006.An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial celldysfunction. The American journal of pathology,169(6), pp.2236-44.